Alzheimer's disease trials recruiting in Illinois

All Alzheimer's disease trials nationally

Cities in Illinois

Recruiting trials in Illinois

• A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
  NCT07033494 · Phase: Phase 2 · Ages: 50 Years to 85 Years · Sex: All (male and female) · Illinois: Elk Grove Village
• A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
  NCT07170150 · Phase: Phase 3 · Ages: 50 Years to 90 Years · Sex: All (male and female) · Illinois: Chicago
• A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
  NCT07602582 · Phase: Phase 3 · Ages: 55 Years and older · Sex: All (male and female) · Illinois: Chicago
• A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
  NCT05552157 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Park Ridge
• A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
  NCT07169578 · Phase: Phase 3 · Ages: 50 Years to 90 Years · Sex: All (male and female) · Illinois: Chicago
• A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)
  NCT07633470 · Phase: Phase 4 · Ages: 50 Years and older · Sex: All (male and female) · Illinois: Palos Hills
• A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
  NCT06647498 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Park Ridge
• A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
  NCT05511363 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · Illinois: Chicago
• A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
  NCT06126224 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · Illinois: Elgin
• A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
  NCT06976216 · Phase: Phase 3 · Ages: 60 Years to 85 Years · Sex: All (male and female) · Illinois: Chicago, Elk Grove Village
• A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
  NCT06976203 · Phase: Phase 3 · Ages: 60 Years to 85 Years · Sex: All (male and female) · Illinois: Chicago, Springfield
• ACP-204 in Adults With Alzheimer's Disease Psychosis
  NCT06159673 · Phase: Phase 2, Phase 3 · Ages: 55 Years to 95 Years · Sex: All (male and female) · Illinois: Elgin
• Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
  NCT06563895 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Illinois: Chicago
• Alzheimer's National Registry for Treatment and Diagnostics(ALZ-NET)
  NCT06170268 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Chicago
• Central Auditory Processing Modulation Underlying Anxiety Reduction Using Clinically Designed Improvisatory Music
  NCT07775625 · Phase: Not applicable (e.g. observational or device study) · Ages: 55 Years and older · Sex: All (male and female) · Illinois: Chicago
• Characterizing Variability in Hearing Aid Outcomes in Among Older Adults With Alzheimer's Dementia
  NCT04240561 · Phase: Not applicable (e.g. observational or device study) · Ages: 50 Years to 90 Years · Sex: All (male and female) · Illinois: Chicago, Evanston
• Communication Bridge 3 Study
  NCT06191198 · Phase: Phase 2 · Ages: 18 Years to 100 Years · Sex: All (male and female) · Illinois: Chicago
• Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
  NCT06584357 · Phase: Not specified · Ages: 60 Years to 90 Years · Sex: All (male and female) · Illinois: Chicago
• Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device
  NCT07701161 · Phase: Not specified · Ages: 40 Years to 90 Years · Sex: All (male and female) · Illinois: Chicago
• Feasibility of Using the Gatorade Sports Science Institute (GSSI) Labs App for Hydration Related Outcomes
  NCT07005895 · Phase: Not specified · Ages: 18 Years to 65 Years · Sex: All (male and female) · Illinois: Chicago
• Late Onset Alzheimer's Disease
  NCT05010603 · Phase: Not specified · Ages: 55 Years and older · Sex: All (male and female) · Illinois: Aurora
• Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
  NCT05397639 · Phase: Phase 3 · Ages: 50 Years to 90 Years · Sex: All (male and female) · Illinois: Chicago
• OTC Hearing Aid and MCI
  NCT06112860 · Phase: Not applicable (e.g. observational or device study) · Ages: 60 Years to 90 Years · Sex: All (male and female) · Illinois: Evanston
• Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
  NCT05980949 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · Illinois: Berwyn, Elgin
• Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
  NCT07177352 · Phase: Phase 3 · Ages: 50 Years to 90 Years · Sex: All (male and female) · Illinois: Chicago
• Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
  NCT06808984 · Phase: Phase 2 · Ages: 55 Years to 90 Years · Sex: All (male and female) · Illinois: Elgin
• Trial-Ready Cohort-Down Syndrome (TRC-DS)
  NCT04165109 · Phase: Not specified · Ages: 25 Years to 55 Years · Sex: All (male and female) · Illinois: Park Ridge
• Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease
  NCT06254469 · Phase: Phase 3 · Ages: 45 Years and older · Sex: All (male and female) · Illinois: Evanston